NYSE American - Nasdaq Real Time Price USD

CEL-SCI Corporation (CVM)

1.4350 -0.0250 (-1.70%)
As of 9:39 AM EDT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Geert R. Kersten Esq. Chief Executive & Financial Officer, Treasurer and Director 702.79k -- 1959
Ms. Patricia B. Prichep Senior VP of Operations & Corporate Secretary 295.18k -- 1951
Dr. Eyal Talor Ph.D. Chief Scientific Officer 351.88k -- 1956
Dr. Daniel H. Zimmerman Ph.D. Senior Vice President of Research & Cellular Immunology 46.08k -- 1941
Mr. John Cipriano Senior Vice President of Regulatory Affairs 246.97k -- 1942

CEL-SCI Corporation

8229 Boone Boulevard
Suite 802
Vienna, VA 22182
United States
703 506 9460 https://cel-sci.com
Sector: 
Healthcare
Industry: 
Biotechnology

Description

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.

Corporate Governance

CEL-SCI Corporation’s ISS Governance QualityScore as of April 1, 2024 is 10. The pillar scores are Audit: 10; Board: 10; Shareholder Rights: 6; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 10, 2024 - May 14, 2024
CEL-SCI Corporation Earnings Call

Related Tickers

NWBO Northwest Biotherapeutics, Inc.
0.4601
0.00%
 
RVPH Reviva Pharmaceuticals Holdings, Inc.
3.0100
-0.33%
 
CTXR Citius Pharmaceuticals, Inc.
0.6951
-2.99%
 
UNCY Unicycive Therapeutics, Inc.
1.0001
-3.80%
 
CARM Carisma Therapeutics, Inc.
1.6614
-1.09%
 
ACET Adicet Bio, Inc.
1.8250
-2.67%
 
ATNM Actinium Pharmaceuticals, Inc.
6.72
-4.82%
 
OCUP Ocuphire Pharma, Inc.
1.5567
+1.79%
 
CYDY CytoDyn Inc.
0.1485
0.00%
 
ANVS Annovis Bio, Inc.
12.89
+1.14%